Jesús
San Miguel Izquierdo

Consultor Investigador

Foto de Jesús

Foto de University of Chicago Medical Center

University of Chicago Medical Center

Chicago, Estados Unidos

Publicacions en col·laboració amb investigadors/es de University of Chicago Medical Center (6)

2022

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501

2021

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
BMC Cancer, Vol. 21, Núm. 1

2020

First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
The Lancet, Vol. 395, Núm. 10218, pp. 132-141

2018

Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
New England Journal of Medicine, Vol. 378, Núm. 6, pp. 518-528

2017

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
British Journal of Haematology, Vol. 177, Núm. 3, pp. 404-413